亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Metabolites of SHetA2 as Anti-Cancer Agents

總結
OSU researchers haveidentified and synthesized amajor metabolite (active molecule) of SHetA2 as well as a conjugate (compound) form of themetabolite.  The conjugate can be used todetermine the specific proteins that promote cancer development, thus providingthe type of information that is necessary to construct new compounds that will improvethe anti-cancer activity of SHetA2.
技術優勢
Effectively induces cell death in cancer cells Shows no toxicity to normal cells in animal trials Human trials slated to begin in near future
技術應用
Cancer treatment
詳細技術說明
None
*Abstract
None
*Background
SHetA2 has previously been identified by OSU researchers asa strong anti-cancer agent that induces apoptosis (cell death) in 8different types of kidney cancer cells and is being developed fortreatment of Polycystic Kidney Disease (PKD). SHetA2 is in the final stages of preclinical testing andsince no toxicity to normal cells has been observed by National CancerInstitute (NCI) in trials with mice, rats, and dogs, clinical trials will beginon human patients in the near future.
*Stage of Development
Prototype is available.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備